Warner Pharmaceutical Co., Ltd. (688799.SH) announced that its subsidiary, Shanghai Zhigen Pharmaceutical Technology Co., Ltd., has recently received the approval notification for the clinical trial of drug ZG-002 issued by the National Medical Products Administration.
Warner Pharmaceutical Co., Ltd. (688799.SH) announced that its subsidiary, Shanghai Zhigen Pharmaceutical Technology Co., Ltd. (Zhigen Pharmaceuticals), has recently received the approval notification for the clinical trial of drug ZG-002 issued by the National Medical Products Administration.
ZG-002 is a new drug with a completely new structure developed by Zhigen Pharmaceuticals, which belongs to the category of class 1 new drugs. Currently, ZG-002 is intended for the treatment of moderate to severe plaque psoriasis.